Case series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: Enhancing safety data
Cephalalgia · 2024
DOI: 10.1177/03331024241273966 ↗Kurz gefasst
Fallbericht in der Zeitschrift Cephalalgia, 2024. Verfasst von Iker Elosua-Bayes und 5 weiteren Autor:innen. Beteiligte Einrichtung: Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelon…. Hauptthemen laut MEDLINE: Calcitonin Gene-Related Peptide, Migraine Disorders, Pregnancy Complications, Antibodies, Monoclonal. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Background
Monoclonal antibodies targeting calcitonin gene-related peptide (CGRP-mAbs) are approved for adult migraine prevention but pose safety concerns in pregnancy. We assess the safety of CGRP-mAbs in the periconceptional period through a case series and literature review.
Methods
Six migraine-diagnosed women received CGRP-mAbs; treatment ceased upon pregnancy. We collected data and conducted safety assessments. To provide a comprehensive context, we performed a literature review.
Results
The series includes three erenumab, two fremanezumab and one galcanezumab case. A fremanezumab recipient experienced miscarriage; severe perinatal asphyxia linked to dystocia occurred with erenumab (140 mg). Database reviews revealed 63 spontaneous abortions, eight premature births, and seven birth defects among 286 World Health Organization and 65 European Medicines Agency cases. These rates align with untreated population rates.
Conclusions
CGRP-mAbs use in the periconceptional period does not lead to clinically significant increase in pregnancy-related pathology or adverse effects on newborns within our case series and the literature reviewed.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Headache and Neurological Pain Research Group, Vall d'Hebron Research Institute, Departament de Medicina, Universitat Autònoma de Barcelona, Barcelona, Spain.
- Headache and Craniofacial pain Unit, Neurology Department, Vall d'Hebron University Hospital, Barcelona, Spain.
ORCID-Profile: Iker Elosua-Bayes, Alicia Alpuente, Edoardo Caronna, Marta Torres-Ferrús, Patricia Pozo-Rosich
Zitieren
APA
Elosua-Bayes, I., Alpuente, A., Melgarejo, L., Caronna, E., Torres-Ferrús, M., & Pozo-Rosich, P. (2024). Case series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: Enhancing safety data. Cephalalgia. https://doi.org/10.1177/03331024241273966
Vancouver
Elosua-Bayes I, Alpuente A, Melgarejo L, Caronna E, Torres-Ferrús M, Pozo-Rosich P. Case series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: Enhancing safety data. Cephalalgia. 2024. doi:10.1177/03331024241273966
BibTeX
@article{ElosuaBayes2024,
author = {Elosua-Bayes, Iker and Alpuente, Alicia and Melgarejo, Laura and Caronna, Edoardo and Torres-Ferrús, Marta and Pozo-Rosich, Patricia},
title = {Case series on monoclonal antibodies targeting calcitonin gene-related peptide in migraine patients during pregnancy: Enhancing safety data},
journal = {Cephalalgia},
year = {2024},
doi = {10.1177/03331024241273966}
}
EUVIMED